Mechanism of action of trastuzumab and scientific update

Seminars in Oncology

Volumn 28, Issue 5 SUPPL. 16, 2001, Pages 4-11

  Baselga, José ^a   Albanell, Joan ^a   Molina, Miguel Angel ^a   Arribas, Joaquin ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; METALLOPROTEINASE; MONOCLONAL ANTIBODY; PROTEIN P185; PROTEIN P27; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL; CELL CYCLE; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION FUNCTION; CYTOTOXICITY; DOWN REGULATION; DRUG MECHANISM; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MITOSIS INHIBITION; ONCOGENE NEU; PRIORITY JOURNAL;

EID: 0035169666     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.28544     Document Type: Conference Paper

References (31)

1. The neu oncogene encodes an epidermal growth factor receptor-related protein
2. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
3. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
4. HER2 monoclonal antibody in patients with HER2-neu-overexpressing metastatic breast cancer
5. HER2 monoclonal antibodies
6. Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic
7. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer
8. Humanization of an anti-p185HER2 antibody for human cancer therapy
9. cdc2 kinase
10. Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1, in breast cancer cells
11. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1
12. Ligand-induced ubiquitination of the epidermal growth factor receptor involves the interaction of the c-Cbl RING finger and UbcH7
13. Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2
14. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin)
15. ErbB2 potentiates breast tumor proliferation through modulation of p27(Kipl)-Cdk2 complex formation: Receptor overexpression does not determine growth dependency
16. Heregulin regulation of Akt/protein kinase B in breast cancer cells
17. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors
18. Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells
19. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets
20. The extracellular domain of pl85/neu is released from the surface of human breast carcinoma cells, SK-BR-3
21. A soluble protein related to the HER-2 proto-oncogene product is released from human breast carcinoma cells
22. The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage
23. Soluble HER-2/neu neutralizes biological effects of anti-HER-2/neu antibody on breast cancer cells in vitro
24. Trastuzumab (Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells
25. HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
26. erbB-2 is a potent oncogene when overexpressed NIH/3T3 cells
27. Different structural alterations up-regulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene
28. Elevated serum c-erbB-2 antigen levels and decreased response to hormonal therapy of breast cancer
29. Membrane protein secretases
30. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein
31. The role of ERBB2 extracellular domain in predicting response to chemotherapy in breast cancer patients